Leerink Partners Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report). The company’s shares closed last Friday at $77.85.

According to, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.9% and a 32.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Protagonist Therapeutics.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $119.36, implying a 53.3% upside from current levels. In a report issued on March 1, Robert W. Baird also maintained a Buy rating on the stock with a $110.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $101.24 and a one-year low of $61.31. Currently, Sarepta Therapeutics has an average volume of 968.9K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year. Most recently, in December 2021, Kathleen Behrens, a Director at SRPT bought 5,000 shares for a total of $50,400.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Read More on SRPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More